scholarly journals Dynamic urinary proteomic analysis in a Walker 256 intracerebral tumor model

2019 ◽  
Vol 8 (7) ◽  
pp. 3553-3565 ◽  
Author(s):  
Linpei Zhang ◽  
Yuqiu Li ◽  
Wenshu Meng ◽  
Yanying Ni ◽  
Youhe Gao
2018 ◽  
Author(s):  
Linpei Zhang ◽  
Yuqiu Li ◽  
Wenshu Meng ◽  
Yanying Ni ◽  
Youhe Gao

AbstractPatients with primary and metastatic brain cancer have an extremely poor prognosis, mostly due to the late diagnosis of disease. Urine, which lacks homeostatic mechanisms, is an ideal biomarker source that accumulates early and highly sensitive changes to provides information about the early stage of disease. A rat model mimicking the local tumor growth process in the brain was established with intracerebral Walker 256 (W256) cell injection. Urine samples were collected on days 3, 5 and 8 after injection and then analyzed by LC-MS/MS. In the intracerebral W256 model, no obvious clinical manifestations changes or abnormal MRI signals were found on days 3 and 5; at these time points, nine proteins were changed significantly in the urine of all 8 tumor rats. On day 8, when tumors were detected by MRI, twenty-five differential proteins were identified, including 10 proteins that have been reported to be closely related to tumor metastasis or brain tumors. The differential urinary proteomes were compared with those from the subcutaneous W256 model and the intracerebral C6 model. Few differential proteins overlapped. Specific differential protein patterns were observed among the three models, indicating that the urinary proteome can reflect the difference when tumor cells with different growth characteristics are inoculated into the brain and when identical tumor cells are inoculated into different areas, specifically, the subcutis and the brain.


1993 ◽  
Vol 78 (6) ◽  
pp. 959-965 ◽  
Author(s):  
Vittorio M. Morreale ◽  
Barbara H. Herman ◽  
Violette Der-Minassian ◽  
Miklós Palkovits ◽  
Phillip Klubes ◽  
...  

✓ A tumor model involving stereotactically implanted culture-reared tumor cells is presented. Stainless steel cannulas were stereotactically and permanently implanted into the caudate nucleus of 30 rats. The animals were separated into two groups. In Group I, 15 animals received a 10-µl injection containing 106 C6 glioblastoma cells (five rats), 106 Walker 256 breast carcinoma cells (five rats), or cell medium (five rats). The coordinates were A(+1.5), L(+3.0), and DV(−5.0). In Group II, the coordinates were changed to A(+1.0), L(+3.0), and DV(−5.0) and the same number of rats received a 1-µl injection containing 105 cells of each tumor in an attempt to produce more focal tumors. Two weeks after implantation, brain sections were stained with cresyl violet and a subset was stained for glial fibrillary acidic protein (GFAP). A computerized morphometric analysis system was used to quantify tumor size. In Group I, the mean C6 tumor areas (± standard error of the mean) at specific coordinates were (in sq mm): A(+4.7) 0.4 ± 0.2; A(+3.7) 3.5 ≥ 1.1; A(+2.7) 5.7 ± 1.7; A(+1.7) 9.5 ± 2.3; A(+0.7) 7.5 ± 3.2; A(−0.3) 3.7 ± 2.9; and A(−1.3) 0.3 ± 0.3. A nearly identical tumor mass and extension into the brain was produced in rats injected with Walker 256 cells. Similar C6 tumor areas were indicated in adjacent sections stained with cresyl violet and GFAP. Tumor was found in the caudate nucleus in all 10 rats, but not in the nucleus accumbens, fornix, or hippocampus. In Group II animals, tumor magnitude and extension into the brain were greatly reduced. The 106 cells in the 10-µl volume was the most reliable tumor load for obtaining uniform tumors in different animals. The similarity of tumor distribution across different animals was indicated by the low variance of tumor area at specific anteroposterior coordinates. Reproducible and well-circumscribed caudate nucleus tumors were produced using this stereotactic procedure.


1991 ◽  
Vol 74 (1) ◽  
pp. 112-115 ◽  
Author(s):  
Wesley A. King ◽  
Keith L. Black ◽  
Kiyonobu Ikezaki ◽  
Scott Conklin ◽  
Donald P. Becker

✓ The efficacy of U-74006F and U-78517F in the treatment of blood-tumor barrier permeability and tumor-associated neurological dysfunction was evaluated in a brain-tumor model in rats. U-74006F is a 21-aminosteroid and U-78517F is a 2-methylamino chroman. Rats with stereotactically implanted Walker 256 tumors were treated with methylprednisolone, U-74006F, U-78517F, or vehicle (0.05 N HCl) on Days 6 through 10 following implantation. Neurological function and vascular permeability were assessed on Day 10. Methylprednisolone and U-74006F were equally effective at preventing neurological dysfunction compared to the control group (p < 0.01); U-78517F was slightly less effective than U-74006F and methylprednisolone but was significantly better than vehicle in preventing neurological dysfunction. Delivery of methylprednisolone resulted in a significant decrease in tumor vascular permeability (p < 0.006) while U-74006F and U-78517F had no effect on permeability. This suggests that U-74006F and U-78517F prevented tumor-associated neurological dysfunction by a mechanism other than decreasing permeability in tumor capillaries, and that U-74006F or U-78517F could prove useful in the treatment of brain tumors.


1980 ◽  
Vol 53 (6) ◽  
pp. 808-815 ◽  
Author(s):  
Naoki Kobayashi ◽  
Norman Allen ◽  
Nancy R. Clendenon ◽  
Li-Wen Ko

✓ The widely used intracerebral tumor implantation method by freehand injection into parietal or hippocampal areas of the rat brain has proven inadequate for reliable experimental therapeutic studies. Problems include poor intracerebral growth yields and significant rates of spread to extracranial tissues, lungs, and spinal cord. Major variables have been examined experimentally on a model using nitrosourea-induced nervous system tumor cell lines in syngeneic rats. A rapid stereotaxic method greatly improved the consistency of tumor placement. The optimal site was found to be the caudate nucleus. The production of a spheroid intracerebral growth was further facilitated by the use of 1% agar in the cell suspension medium and by an injection volume of 10 µl containing at least 104 cells. Further improvements involved injection technique and flushing of the operative field. These modifications have resulted in a 99% to 100% yield of intracerebral growth, with a marked reduction in the number and size of extracranial extensions and with distant metastasis rates of 0% to 5%. These results have continually improved with further experience. The method is satisfactory for radiation and chemotherapeutic trials in which survival time as an index of tumor size may be used as an end point.


2017 ◽  
Vol 14 (4) ◽  
pp. 3868-3873 ◽  
Author(s):  
Li Feng ◽  
Ling Qin ◽  
Dan Guo ◽  
Daping Deng ◽  
Feng Lu ◽  
...  

2015 ◽  
Vol 28 (1) ◽  
pp. 101-115 ◽  
Author(s):  
L. Fracaro ◽  
F. C. V. Frez ◽  
B. C. Silva ◽  
G. E. Vicentini ◽  
S. R. G. de Souza ◽  
...  

2015 ◽  
Vol 3 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Tolga Turan Dundar ◽  
Mehmet Hakan Seyithanoglu ◽  
Sefika Korpinar ◽  
Raziye Atar ◽  
Sevket Evran

2007 ◽  
Vol 177 (4S) ◽  
pp. 297-297
Author(s):  
Kristina Schwamborn ◽  
Rene Krieg ◽  
Ruth Knüchel-Clarke ◽  
Joachim Grosse ◽  
Gerhard Jakse

Sign in / Sign up

Export Citation Format

Share Document